Actualising the power of antibody-drug conjugates as cancer therapeutics
European Pharmaceutical Review
AUGUST 24, 2022
there are 14 approved ADCs on the global market, all for oncology indications, and over 140 ADCs currently in clinical development” More than 20 years ago, the first ADC, Mylotarg, was approved for use in patients with relapsed or refractory acute myeloid leukaemia (AML). The culmination of two decades of learning.
83 
Let's personalize your content